Shire (SHPG) PT Set at $225.00 by Cowen

Cowen set a $225.00 target price on Shire (NASDAQ:SHPG) in a research note published on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also commented on the stock. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a buy rating in a research note on Wednesday, January 3rd. Piper Jaffray Companies reiterated a hold rating on shares of Shire in a research note on Wednesday, January 3rd. Zacks Investment Research lowered shares of Shire from a hold rating to a sell rating in a research note on Tuesday, January 2nd. ValuEngine lowered shares of Shire from a buy rating to a hold rating in a research note on Sunday, December 31st. Finally, Liberum Capital reiterated a hold rating on shares of Shire in a research note on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $212.18.

Shire (NASDAQ SHPG) traded down $7.76 during midday trading on Friday, hitting $149.10. 2,740,000 shares of the company traded hands, compared to its average volume of 961,260. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. The company has a market cap of $45,410.00, a price-to-earnings ratio of 28.08, a PEG ratio of 0.84 and a beta of 1.59. Shire has a 1 year low of $137.17 and a 1 year high of $192.15.

Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, topping the consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion during the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the firm earned $3.17 EPS. analysts anticipate that Shire will post 15 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new stake in shares of Shire in the 3rd quarter valued at $159,000. Sterling Capital Management LLC boosted its holdings in shares of Shire by 26,182.4% in the 3rd quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock valued at $72,649,000 after acquiring an additional 472,592 shares during the last quarter. Afam Capital Inc. boosted its holdings in shares of Shire by 3.0% in the 3rd quarter. Afam Capital Inc. now owns 30,761 shares of the biopharmaceutical company’s stock valued at $4,711,000 after acquiring an additional 882 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in Shire by 16.4% during the third quarter. Neuberger Berman Group LLC now owns 21,789 shares of the biopharmaceutical company’s stock worth $3,337,000 after buying an additional 3,076 shares in the last quarter. Finally, Lumbard & Kellner LLC boosted its holdings in Shire by 46.9% during the third quarter. Lumbard & Kellner LLC now owns 26,685 shares of the biopharmaceutical company’s stock worth $4,087,000 after buying an additional 8,515 shares in the last quarter. 20.19% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/08/shire-shpg-pt-set-at-225-00-by-cowen.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

What are top analysts saying about Shire? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit